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Abstract  
  
Introduction: Electronic virtual chromoendoscopy (EVC) can demonstrate ongoing 
disease activity in ulcerative colitis (UC) even when Mayo subscores suggest healing. 
However, applicability of EVC technology outside the expert setting has yet to be 
determined.  
Methods: 15 participants across five centres reviewed a computerised training module 
outlining high definition (HD) and EVC (i-Scan) colonoscopy modes. Inter-observer 
agreement was then tested (Mayo score, UCEIS and the Paddington International virtual 
ChromoendoScopy ScOre [PICaSSO] for UC), using a colonoscopy video library (n=30 
cases reviewed pre- and n=30 post-training). Knowledge sustainability was re-tested in a 
second round (n=42 cases; 9/15 participants), 6 months post-training provision. 
Results: Pre-training intraclass correlation coefficients (ICC) were good for the Mayo 
endoscopic subscore (ICC:0.775), UCEIS scoring erosions/ulcers (ICC:0.770) and 
UCEIS overall (ICC:0.786), and for mucosal (ICC:0.754) and vascular components of 
PICaSSO (ICC:0.622). For the vascular components of UCEIS, agreement was only 
moderate (ICC:0.429), and did not enhance post-training (ICC:0.417); unlike for 
PICaSSO which improved (mucosal ICC:0.848; vascular: 0.746). Histological correlation 
using the New York Mt. Sinai System was strong for both PICaSSO components 
(Spearman’s rho for mucosal: 0.925, and vascular: 0.873; p<0.001 for both). Moreover, 
accuracy in specifically discriminating quiescent from mild histological strata was 
strongest for PICaSSO (AUROC for mucosal: 0.781; vascular: 0.715), compared to Mayo 
(AUROC:0.708) and UCEIS (AUROC for UCEIS overall: 0.705; vascular: 0.562; 
bleeding: 0.645; erosions/ulcers: 0.696). Inter-rater reliability for PICaSSO was sustained 
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by  round two participants (Round 1 and 2 ICC for mucosal: 0.873 and 0.869, 
respectively; and vascular: 0.715 and 0.783, respectively), together with histological 
correlation (rho mucosal: 0.934, vascular: 0.938; p<0.001 for both). 
Conclusion: PICaSSO demonstrates good inter-observer agreement across all levels of 
experience, providing excellent correlation with histology. Given ability to discriminate 
subtle endoscopic features, PICaSSO may be applied to refine stratified treatment 
paradigms for UC patients. 
 
Keywords:  Colonoscopy, endoscopic remission, histological remission, inflammatory 
bowel disease, mucosal healing, risk stratification 
 
 
 
Study Highlights 
 
What is already known on the issue? 
 
Conventional white light endoscopy have limitations in defining inflammation in 
ulcerative colitis, especially at the milder end of the spectrum and mucosal healing. More 
detailed assessment such as histologic scoring may better predict relapses. Electronic 
virtual chromoendoscopy (EVC) can demonstrate ongoing disease activity even when 
Mayo scores suggest healing.  EVC score (PICaSSO) was designed and validated by 
international expert endoscopists in EVC.  However, applicability of EVC scoring in UC 
requires validation outside the expert setting. 
 
 
 
 
  8 
How was the study done? 
 
A training module was first developed. Fifteen participants across five general 
gastroenterology and colorectal divisions reviewed a computerised training module 
outlining high definition (HD) and EVC (i-Scan) colonoscopy modes. Inter-observer 
agreement was then tested (Mayo score, UCEIS and the Paddington International virtual 
ChromoendoScopy ScOre [PICaSSO] for UC), using a colonoscopy video library (n=30 
cases reviewed pre- and n=30 post-training). An abbreviated and simple PICaSSO score 
(PICaSSO-ab) was created. Knowledge sustainability was re-tested in a second round 
(n=42 cases; 9/15 participants), 6 months post-training provision. 
 
What were the main findings? 
 
Agreement for vascular components of PICaSSO was good (ICC 0.622) and better than 
for the vascular components of UCEIS, where agreement was only moderate 
(ICC:0.429), and did not enhance post-training (ICC:0.417). This was unlike PICaSSO 
which improved (mucosal ICC: 0.848; vascular: 0.746). Histological correlation using the 
New York Mt. Sinai System was strong for both PICaSSO components (Spearman’s rho 
for mucosal: 0.925, and vascular: 0.873; p<0.001 for both). Moreover, accuracy in 
specifically discriminating quiescent from mild histological strata was strongest for 
PICaSSO (AUROC for mucosal: 0.781; vascular: 0.715), compared to Mayo 
(AUROC:0.708) and UCEIS (AUROC for UCEIS overall: 0.705; vascular: 0.562; 
bleeding: 0.645; erosions/ulcers: 0.696). Inter-rater reliability for PICaSSO was sustained 
in round two participants together with histological correlation (rho mucosal: 0.934, 
vascular: 0.938; p<0.001 for both). 
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What do these results add to the current body of knowledge? 
 
The Paddington International virtual ChromoendoScopy ScOre (PICaSSO) achieves good 
inter-rater reliability post-training, across all levels of endoscopy experience.  Correlation 
between PICaSSO and histology is strong, with performance accuracy that is sustainable 
over time. PICaSSO provides the most accurate discrimination between quiescent and 
mild histological disease activity, compared to the Mayo score and UCEIS.   
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INTRODUCTION 
 
Treatment paradigms in ulcerative colitis (UC) have been revolutionised by the advent of 
novel, targeted therapies;
1–6
 with mucosal healing (MH) a critical endpoint for clinical 
trials and in practice.
7–9
 Consequently, many endoscopic indices have been devised in 
UC,
7,8,10
 with the Mayo endoscopic subscore the most widely adopted.
11
 Despite its 
popularity, the Mayo score has been criticised for including descriptors that overlap 
between different tiers, inclusion of terms open to subjective interpretation (e.g. 
friability), multiple descriptors within same scoring tiers, lack of clear definition of 
mucosal healing and wide inter-observer variability. Additionally, clinical trials in UC 
often classify Mayo 0–1 collectively as MH,1,12 despite significant differences in the 
incidence of disease relapse and colectomy between the two groups.
13,14
 Furthermore, 
abnormalities in fine vascular pattern rather than definitive loss, is generally apparent 
with usage of contemporary high resolution colonoscopy; with the Mayo endoscopic 
subscore largely representing t legacy of older generation endoscopes or even rigid 
sigmoidoscopy. More contemporary scoring systems have been proposed, most notably 
the validated Ulcerative Colitis Endoscopic Index of Severity (UCEIS),
15,16
 . The UCEIS 
demonstrates good correlation with disease severity and prediction of clinical outcome by 
experts in the field, 
17–19
 but does not define the endoscopic features of MH in UC. 
UCEIS also categorises ‘loss’ of vascular pattern, rather than describing the fine vascular 
abnormalities visible at high resolution. 
 
A notable caveat of existing endoscopic scoring systems is that all were derived using 
conventional white light endoscopy (WLE). Data from the Oxford group illustrates that 
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>20% of patients exhibit persistent inflammation histologically, even after attaining 
endoscopic remission as determined by WLE.
20
 Indeed, histological remission is a target 
distinct from endoscopic mucosal healing, and may better predict the incidence of future 
clinical events.
20
 However this may reflect the older generation of endoscopes with lower 
resolution capabilities. In a similar vein, it has been shown that 30% of individuals 
having a Mayo endoscopic subscore of 0 exhibit persistent inflammatory mucosal 
changes when re-examined with high definition (HD) electronic virtual 
chromoendoscopy (EVC).
21
 This has furthered development of a dedicated EVC scoring 
system to better assess inflammation, and quantify how the measure of abnormal vascular 
pattern correlates with histology.
22
 However, there is clear need for effective and 
validated training in EVC technology; and computer or web-based teaching may offer an 
opportunity for easy, and inexpensive delivery. Indeed, with new technology the 
paradigms of endoscopic classification in UC are changing.  
 
The Paddington International virtual ChromoendoScopy ScOre (PICaSSO), developed 
and validated following provision of a comprehensive computerised training module, 
represents the first EVC-based assessment tool for systematically evaluating disease 
activity in UC.
22
 Despite good inter-observer agreement between raters and strong 
correlation with histological indices, a limitation to the original study is that all 
participants were dedicated endoscopy experts; whereas operating characteristics in the 
gastroenterology community as a whole has not been determined. Thus, the principal aim 
of this study is to validate inter-rater reliability of PICaSSO specifically in a non-expert 
setting, across a breadth of endoscopy experience and to assess the sustainability of 
diagnostic performance over time after training. We also attempted to simplify PICaSSO 
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for use by those less experienced in EVC assessment, and develop a standardised training 
module that may be adopted in wider clinical practice. 
  
METHODS 
 
We tested the external reproducibility of PICaSSO in experienced consultants and 
trainees, who had no prior exposure to EVC iSCAN virtual Chromoendoscopy. 
Investigators for this study comprised practising gastroenterologists and colorectal 
surgeons from five United Kingdom (UK) hospitals (Figure 1). 
 
Training module design 
One gastroenterologist (MI) with expertise in EVC and optical diagnosis in IBD 
developed a training module based on pre-existing UC scoring systems and 
PICaSSO;
11,15,22
 encompassing the following characteristics: 
▸  The clinical importance in differentiation between quiescent vs. mild activity in UC.  
▸ Limitations of Mayo endoscopic scoring and UCEIS. 
▸ The PICaSSO EVC score and detailed characterisation of mucosal and vascular 
changes.  
 
MI did not score videos in the study. 
 
The training module consisted of 100 high-resolution endoscopic pictures and 10 videos, 
and was assessed by all the participants with direct feedback and stepwise discussion. 
These illustrated the entire spectrum of inflammatory mucosal and vascular changes 
  14 
including mucosal healing in UC (Figure 2 and Supplementary Video 1 & VCE 
PICaSSO training module with a link to it via website) 
 
A. Round one 
Pre-training  
All participants were presented with 30 colonoscopy videos (quiescent, n = 10; mild, n = 
7; moderate, n = 6; severe, n = 7 by histology grading) recorded in high definition white 
light and i-SCAN modes (EPKi 7000 Pentax EC-3490Fi in 3 settings, high-definition 
white light i-SCAN 1 and EVC i-SCAN 2 and 3 modes integrated into the endoscope 
hand piece that can be operated by simply pressing on the button),. Each rater  scored 
individual videos: using a standardised case record form as indicated previously,
22
 prior 
to any training provision (pre-training component). Participants were also provided with a 
printed sheet, listing the individual anchor points of  the Mayo score, UCEIS and 
PICaSSO; but with no illustrations/photographic material shown. 
 
Training module provision 
Thereafter, the pre-designed 60-minute comprehensive training module was delivered (by 
MI and SG), including an introduction to the study, explanation of endoscopic scores in 
use, and detailing all the endoscopic findings (different selection from the pre-/post-
training video library) of varying grades of inflammation in UC; illustrated via HD and 
EVC modes (Figure 2, Supplementary EVC PICaSSO Training module and Table 
1A).  
 
Post-training 
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Following training, each participant scored the 30 videos in a different random order  
(post-training component) and the results compared. All videos (in the pre- and post-
training modules) were scored according to the Mayo endoscopic subscore,
11
 UCEIS
15,16
 
and PICASSO.
22
 In addition to the original, highly detailed scoring system proposed by 
Iacucci et al.,
22
 the inter-rater reliability of an abbreviated, simpler version of PICaSSO 
was also tested (PICaSSO-Ab.) (Table 1B). The original PICaSSO score was designed 
with items that had the potential to be simplified based on the operating characteristics in 
the original validation.
22 
The abbreviated PICaSSO score was devised based on the 
results of the multivariate analysis of the endoscopic predictors of the grade of 
inflammation at histology, done item by item. The endoscopic subcategories of mucosal 
or intraluminal bleeding with round dilated or crowded tortuous superficial vessels as 
well as erosions or ulcerations, discrete or diffuse, were not important predictors of the 
multivariate  analysis of grade of inflammation at histology.  
 
B. Round two 
In the second validation phase we assessed the long-term learning, sustainability and 
diagnostic performance of the PICaSSO endoscopic scoring system in UC. All 
participants were invited to attend a second round after a six-month interval (during 
which no exposure to PICaSSO scoring and i-SCAN technology took place). Each 
individual scored a new set of 42 videos (quiescent, n = 15; mild, n = 8; moderate, n = 6; 
severe, n = 13), which were different from the 30 videos previously assessed. 
 
Video library selection for both rounds 
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A total of 72 unique, high-quality video clips (30 + 42) representing collections of 
different grades of inflammation were selected in the first and second phases of the study 
from an existing library. This anonymised library was collated by one investigator (MI) 
from colonoscopies assessing the breadth of inflammatory activity observed in UC 
patients (Figure 2). Videos were saved in Audio Video Interleave (AVI) format (S-video 
output to endoPRO legacy, MPS Motion Picture Studio; standard definition image 
capture in MPEG3). 
 
A single pathologist (XG) blinded to the results of endoscopic scoring scored the 
histological severity of disease for each video, according to the New York Mt. Sinai 
System as proposed by Hefti et al.
23
 
 
Data interpretation and analysis 
Given the large number of participants and a desire to maintain the ordinal hierarchy of 
scoring, agreement between participants was tested using intra-class correlation 
coefficients (ICC).
26
 Results of ICC analysis were classified as very good (coefficients: 
0.81 – 1.00), good (0.61 – 0.80), moderate (0.41 – 0.60), fair (0.21 – 0.40) and poor 
(<0.21).
24
 In addition to the ICCs, a ‘pairs of raters’ approach was also used. This 
compared the scores given every possible pair of participants, and was reported as the 
proportion of those that matched. The resulting statistic represented the probability that 
two randomly selected participants would give the same exact score for a given patient. 
 
Correlations between the individual endoscopic scores, averaged across all participants, 
and histological indices of disease severity were assessed using Spearman’s Rank 
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correlation coefficients (rho). All analyses were performed using IBM SPSS 22 (IBM 
Corp. Armonk, NY), with p<0.05 deemed to be indicative of statistical significance 
throughout.  
 
RESULTS 
Participants  
Participants for this study in round one comprised practicing gastroenterologists and 
colorectal surgeons at consultant (n = 7) and trainee level (n = 8) from five UK hospitals. 
Lifetime procedure counts varied between 200 colonoscopies for the most junior 
participant (range 200 – 450), to 4,500 for the most senior (range 2,000 – 4,500). Whilst 
participants indicated familiarity with the Mayo endoscopic subscore and UCEIS, and 
narrowband imaging (NBI) endoscopic system, none   were experienced in i-SCAN EVC 
technology.  
 
Inter-observer reliability of endoscopic scores following computerised module 
training 
The inter-rater agreement was good for the Mayo score, the UCEIS score (as well as the 
erosions/ulcers and bleeding components), and for both the PICaSSO mucosal and 
vascular patterns in the pre-training module (Table 2). Inter-rater agreement was weakest 
for the vascular component of UCEIS, for which agreement was only moderate. 
 
After training, inter-rater agreement improved for the majority of scores considered, with 
the Mayo score, the overall UCEIS score (as well as the individual erosion/ulcer 
component) and the PICaSSO vascular pattern now achieving ‘very good’ agreement 
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(ICC>0.8). The only score not to improve with training was the vascular component of 
UCEIS, for which agreement remained moderate. 
 
 
 
Correlation of the PICaSSO EVC score with histological indices 
In the data collected post-training, strong correlations were detected between the 
histological score and PICaSSO for both the full and abbreviated (PICaSSO-ab) versions 
of the mucosal (Spearman’s rho: 0.925 [95% CI: 0.843 – 0.965], p<0.0001; and 0.894 
[0.783 – 0.950], p<0.0001; respectively) and vascular components (rho: 0.873 [0.743 – 
0.940], p<0.0001; and 0.889 [0.772 – 0.947], p<0.0001; respectively) (Figure 3). Similar 
correlations were also detected between the histological score and both the UCEIS and 
the Mayo endoscopic subscores (UCEIS vascular component: 0.829 [0.662 – 0.918], 
bleeding component: 0.913 [0.819 – 0.959], mucosal component: 0.872 [0.742 – 0.939], 
overall: 0.887 [0.770 – 0.947]; Mayo endoscopic subscore: 0.876 [0.748 – 0.941]; p 
values <0.0001 for all). 
 
Inter-rater reliability across histological strata 
Next, the degree of reliability across each histological strata was determined. By 
analysing every possible combination of rater scores (n = 15 participants; 105 possible 
rater combinations), we found that agreement was stronger for PICaSSO-Ab. vs. the full 
PICaSSO system across both components, being greatest at extremes of disease activity 
(Figure 4) (Supplementary Table 1), though of course PICaSSO-Ab lost some of the 
details of the full PICaSSO. When observing the percentage agreement across all tested 
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scoring systems, it was evident that mucosal components in PICaSSO and UCEIS had 
consistently better inter-rater reliability than their vascular/bleeding counterparts.  
 
Accuracy in predicting quiescent disease 
A Mayo score of 0 is commonly applied as an endoscopic endpoint in clinical trials, 
although histological disease activity may yet persist and better forecast outcomes for UC 
patients.
20,21
 Thus, in an effort to better discriminate quiescent vs. mild histological 
disease activity we conducted sensitivity analysis for each endoscopic scoring system. 
Evaluating all individual rater responses on a per-video basis (n = 450 data points), the 
most accurate scoring system predictive of quiescent disease was the mucosal component 
of PICaSSO (area under the receiver operator characteristic curve [AUROC]: 0.917, 95% 
CI: 0.890 – 0.943), p < 0.001; Figure 5a). Moreover, in a restricted analysis of only 
those cases capturing quiescent vs. mild histological disease activity (n = 255 data 
points), the highest performing scoring system was PICaSSO across both components 
(Figure 5b) (Supplementary Table 3).  
 
Sustainability of performance of PICaSSO over time  
A second round of video scoring took place following a 6-month interval, in which 
participants were invited to score a further 42 videos. Of the original fifteen raters, 9 
responded to the invitation and participated in round two (5 consultants and 4 trainees).  
No participant was exposed to iscan endoscopic system ( or other EVC technology) to 
assess UC during this period. The level of inter-rater reliability in this group at the second 
session was found to be consistent with that observed in the post-training assessment in 
round one (results for round one and round two for the 9/15 participants are provided in 
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Table 3). The same was true for the pairs-of-raters approach, broken down by 
histological strata (Supplementary Table 2).  
 
Correlations between the PICaSSO score and histological strata also remained strong for 
both the full (Spearman’s rho for mucosal component: 0.934 [0.878 – 0.965]; vascular 
component: 0.938 [0.885 – 0.967]; p<0.0001 for both) and abbreviated systems (mucosal 
component: 0.927 [0.867 – 0.961]; vascular component: 0.909 [0.836 – 0.951], 
respectively; p<0.0001 for both). 
 
DISCUSSION 
 
We show that the newly developed EVC score for UC, PICaSSO, detailing mucosal and 
vascular components through HD i-SCAN technology, is easy to learn, displays very 
good reliability between raters at all levels of endoscopy training after provision of a 
computerised training module. We further demonstrate that the diagnostic performance of 
PICaSSO was sustained over time (six months); and that the predictive accuracy is 
greater than the Mayo score and UCEIS in permitting discrimination between quiescent 
vs. mild histological disease activity. To our knowledge, this is the first effective and 
standardised training module that can be applied across all levels of endoscopy 
experience, which allows EVC scoring modalities to be implemented in clinical practice.  
 
Accurate assessment of disease activity is critical for guiding treatment decisions in UC, 
both with regard to escalating and deescalating therapy, as well as recognition of 
dysplastic change. In this regard, endoscopic image-enhancement allows visualisation of 
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normal and abnormal mucosa complementary to conventional white light endoscopic 
imaging.
10
 During colonoscopic surveillance, EVC is also proven to better lesion 
recognition and characterisation, and facilitate precision-targeted biopsies to a greater 
degree than standard white-light endoscopy.
25
 However, despite widespread availability 
for over a decade, utilising EVC beyond academic research has been limited by lack of 
standardised training and paucity of guideline-directed implementation into routine 
clinical practice. In the meantime, EVC technology has progressed and been refined 
rapidly. 
 
The ability to train endoscopists without experience in EVC technology to reach 
acceptable levels of competence has been the focus of the recent white paper by the 
American Gastroenterological Association (AGA).
26
 Therein, it was acknowledged that 
computer-based training modules with ongoing reflective feedback are an effective ‘tool 
for training,’ particularly with reference to lesion recognition using NBI. Along similar 
lines, our study represents the first external validation of an EVC scoring system assessing 
ulcerative colitis disease activity across a breadth of colonoscopy experience. Importantly, 
the pool of endoscopists who participated all denied familiarity with i-SCAN technology. 
Through provision of a computerised training module, we demonstrate very good inter-
rater reliability of PICaSSO and strong correlation with histological activity, both of 
which are sustained over time. This suggests that the learning curve for PICaSSO is short, 
effective, and accomplishable within several hours of concentrated training. The testament 
to our exercise is perhaps best highlighted by the fact that for all tested scoring systems 
(except the UCEIS component of vascular change), the degree of reliability improved 
following training provision. Moreover, we were in line with other recent studies 
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independently evaluating the usefulness of brief training interventions in improving 
diagnostic accuracy of colonic polyp recognition for clinicians with varying endoscopic 
expertise.
27–30
  
 
Preliminary data using magnifying NBI of colonic mucosa suggests that UC relapse may 
be predicted by vascular changes alone, without considering the mucosal findings.
31
 The 
vascular features captured by NBI as well as BLI are similar to i-SCAN, and it is probable 
that a common EVC score may be developed in future irrespective of the chosen platform; 
a concept we hope to develop as a prospective multicenter endeavour which is now 
ongoing.  Indeed, endoscopic features of mucosal and vascular healing may be defined 
across all EVC platforms (iSCAN , NBI and BLI) with scoring tiers very similar to the 
PICaSSO score. We are evaluating this in a multicentre setting. To this effect we have 
provided matching images of different grades of activity for NBI and BLI to indicate how  
translation to other endoscopic EVC platforms may be feasible. (Figure 6,7,8) The 
endoscopic findings of mucosal and vascular healing – such as continuous/regular crypts, 
crypts not visible (scar), discontinuous and or dilated/elongated crypts; and vascular 
changes such as ‘roundish’ appearance following crypt architecture, vessels not visible 
(scar), and sparse deep vessels without dilatation – are individually and collectively shown 
to predict histological remission.
22
 Their critical importance of these concepts is perhaps 
best highlighted when discriminating quiescent vs. mild histological disease activity in 
sensitivity analysis, wherein both PICaSSO components performed best across all scoring 
systems tested; potentially impacting real-time treatment decisions and stratified patient 
care. 
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Early studies with other scoring systems have shown a large variance in agreement 
between gastroenterologists to assess the endoscopic activity in UC.
32
 However, the 
intraclass correlation coefficients we obtained for both PICaSSO components were 
comparable to the Mayo endoscopic subscore and UCEIS; both internally and versus 
results of central readership in certain clinical trials.
33
 Of note, conventional methods of 
testing inter-rater reliability that only apply kappa statistics do not allow accurate 
weighting, and suffer from the issue of joint-probability by treating data as nominal rather 
than ordinal in nature. For instance, the variability in scoring between luminal bleeding 
and vessel dilatation is clearly greater than the clinical divide between vessel dilation and 
vascular crowding, which is captured by ICC methodology but not via Kappa statistics. 
Whilst Cohen’s weighted Kappa may allow a degree of hierarchy to be maintained, this is 
not possible to apply in our study given the large number of individual raters. Intraclass 
correlation coefficients are also ‘chance-corrected,’ resulting in a more accurate measure 
of agreement and not affected by the different number of components in any given 
score.
34
 
 
One of the pre-requisites for ensuring completeness to our video library, both in the 
training module and for test scoring, was to encompass the full spectrum of inflammatory 
activity observed in ulcerative colitis. In so doing, we found that study participants 
performed better in assessing mucosal lesions as opposed to vascular patterns, akin to the 
expert panel that comprised the original London Paddington consensus.
22
 This can 
partially be explained by the fact that EVC is a relatively new concept in UC, although 
the vascular component of the UCEIS also under performed. Thus, we need to 
continually improve the vascular component both for definition and for training purposes. 
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In this study, an abbreviated version of PICaSSO was also proposed, given that early 
mucosal and vascular changes exclude the presence of erosions/ulcers and onset of 
bleeding, respectively; hence subtlety and detail in scoring carries less relevance during 
overt, active disease states. Despite this restriction, inter-rater reliability was sustained, 
durable over time, and exhibited strong parallels with histological correlates. Moreover, 
PICaSSO-Ab. system, for both mucosal and vascular components, improved the level of 
agreement across individual histological strata. The advantages of PICaSSO-Ab. are 
mirrored in its simplicity; although further in-depth learning curve assessment is critical, 
with an extended teaching phase as proposed by the original investigators.
22
  
This study has several limitations . The  same videos have been used in  
the pre and post test in round 1 which was performed in the same day. There is a 
possibility of recall bias despite the videos had been scored in randomized  different 
order. It is also difficult to recall PICaSSO..In any event , the K interobserver agreement  
between  raters was  good and sustained after 6 months where in  a completely new set  
of videoclips were scored. 
 In addition, the PiCaSSO score requires validation in real time clinical practice ,and 
correlation with outcomes that are clinically meaningful; specifically relapses in active 
disease, the frequency of hospitalisation episodes and time to colectomy especially within 
of patients exhibiting endoscopic Mayo Scores of 0 and 1. Further work is also ongoing 
to converge single yet comprehensive and accurate scoring system applicable across all 
EVC platforms. 
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In conclusion, PICaSSO displays very good and sustained reliability between raters, 
both experienced and less experienced endoscopists, after delivery of a standardised 
training module with good correlation against histological gradings. Future 
endeavours will need to evaluate the performance of PICaSSO across a multicentre 
prospective setting in real time (currently underway), in addition to assessing how 
clinical outcome prediction can be enhanced through EVC technology in UC.
19,26
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Table 1: Components of the PICaSSO EVC score in ulcerative colitis (full and 
abbreviated) 
Mucosal architecture Vascular architecture 
A) PICaSSO (full version) 
0. No mucosal defect 0. Vessels without dilatation 
A) Continuous / regular crypt architecture A) Roundish; following crypt architecture 
B) Crypts not visible (scar)  B) Vessels not visible (scar) 
C) Discontinuous and/or dilated/elongated crypts C) Sparse (deep) vessels without dilatation 
I. Micro-erosions or crypt abscess I. Vessels with dilatation 
1) discrete A) Roundish with dilatation 
2) patchy B) Crowded or tortuous superficial vessels with 
dilatation 3) diffuse 
II. Erosions (size <5mm in diameter) II. Intramucosal bleeding 
1) discrete A) With round, dilated vessels 
2) patchy B) With crowded or tortuous superficial vessels that are 
dilated 3) diffuse 
III. Ulceration (size >5mm in diameter) III. Intraluminal bleeding 
1) discrete A) With round, dilated vessels 
2) patchy B) With crowded or tortuous superficial vessels that are 
dilated 3) diffuse 
B) PICaSSO-Ab. (abbreviated version) 
0. No mucosal defect 0. Vessels without dilatation 
Any from: Any from: 
- Continuous / regular crypt architecture - Roundish; following crypt architecture 
- Crypts not visible (scar)  - Vessels not visible (scar) 
- Discontinuous and/or dilated/elongated crypts - Sparse (deep) vessels without dilatation 
I. Micro-erosions or crypt abscess I. Vessels with dilatation 
- Any pattern of discrete/patchy/diffuse involvement: - Vessels that are either roundish and dilated; or 
crowded and tortuous with dilatation 
II. Erosions (size <5mm in diameter) II. Intramucosal bleeding 
III. Ulceration (size >5mm in diameter) III. Intraluminal bleeding 
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Table 2: Intraclass correlation coefficients (ICC) pre- and post-training modules 
(Round 1) 
 Pre-training 
ICC (95% CI) 
Post-training 
ICC (95% CI) 
Mayo score 0.775 (0.678 – 0.864) 0.818 (0.731 – 0.894) 
UCEIS Total score 0.786 (0.692 – 0.872) 0.833 (0.753 – 0.903) 
- UCEIS vascular pattern 0.429 (0.306 – 0.588) 0.417 (0.295 – 0.577) 
- UCEIS bleeding pattern 0.689 (0.574 – 0.804) 0.726 (0.617 – 0.831) 
- UCEIS erosion / ulcer pattern 0.770 (0.672 – 0.861) 0.810 (0.723 – 0.887) 
PICaSSO mucosal component  0.754 (0.651 – 0.850) 0.848 (0.773 – 0.913) 
PICaSSO-Ab. mucosal (abbreviated version) 0.754 (0.651 – 0.851) 0.826 (0.743 – 0.899) 
PICaSSO vascular component  0.657 (0.536 – 0.781) 0.739 (0.631 – 0.842) 
PICaSSO-Ab. vascular (abbreviated version) 0.622 (0.498 – 0.754) 0.746 (0.640 – 0.847) 
ICCs are from a two-way random model with absolute agreement, and are for single 
measures (n = 15 participants). All values are significant at a p<0.001.  
 
Abbreviations: CI, confidence interval; EVC, endoscopic virtual chromoendoscopy score; 
ICC, intraclass correlation coefficient; UCEIS, ulcerative colitis endoscopic index of 
disease severity   
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Table 3: Intraclass correlation coefficients (ICC) for the participants attending 
Round 1 and Round 2* 
 Round 1 post-training 
ICC (95% CI) 
Round 2 
ICC (95% CI) 
Mayo score 0.835 (0.745 – 0.906) 0.881 (0.823 – 0.926) 
UCEIS Total score 0.844 (0.763 – 0.911) 0.881 (0.827 – 0.925) 
- UCEIS vascular pattern 0.488 (0.349 – 0.650) 0.602 (0.487 – 0.722) 
- UCEIS bleeding pattern 0.737 (0.623 – 0.841) 0.789 (0.704 – 0.863) 
- UCEIS erosion / ulcer pattern 0.825 (0.739 – 0.898) 0.869 (0.812 – 0.917) 
PICaSSO mucosal component  0.873 (0.805 – 0.929) 0.869 (0.812 – 0.917) 
PICaSSO-Ab. mucosal (abbreviated version) 0.852 (0.774 – 0.916) 0.854 (0.792 – 0.907) 
PICaSSO vascular component  0.715 (0.597 – 0.826) 0.783 (0.695 – 0.860) 
PICaSSO-Ab. vascular (abbreviated version) 0.736 (0.622 – 0.840) 0.772 (0.682 – 0.851) 
*Nine / 15 participants attended on both round 1 (30 videos) and round 2 (42 videos). 
 
ICCs are from a two-way random model with absolute agreement, and are for single 
measures. All values are significant at a p<0.001.  
 
Abbreviations: CI, confidence interval; EVC, endoscopic virtual chromoendoscopy 
score; ICC, intraclass correlation coefficient; UCEIS, ulcerative colitis endoscopic index 
of disease severity 
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Figure 1: Study overview 
 
Flow chart of study design, illustrating construction and delivery of the training module, 
and subsequent assessment of reliability and performance accuracy. Histological strata 
are according to the New York Mt. Sinai System proposed by Hefti et al.
23
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Figure 2: Representative photos of  PICaSSO mucosal and vascular endoscopic 
findings captured by electronic virtual chromoendoscopyin different 
grade of inflammation  
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Figure 3: Correlation between the EVC score and histology in ulcerative colitis  
 
Graphical representation of score distribution for PICaSSO according to histological 
severity of disease. Results are shown for [A] the mucosal component and [B] vascular 
components of the EVC score. Each point represents the average score per video over the 
15 participants (post-training). N numbers characterise the number of videos tested in 
each histological category in the post-training module. Histological strata are presented 
according to the New York Mount Sinai scoring system.
23
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Figure 4: Inter-rater reliability across histological strata  
 
Inter-rater reliability for each score across individual histological strata measured on day 
one (post-training) are presented as percentage agreement for every possible combination 
of raters (15 participants; n =105 possible pairings). 
 
* Data for abbreviated PICaSSO system (PICaSSO-Ab.) is shown 
NYMSS, New York Mt. Sinai System; UCEIS, ulcerative colitis endoscopic index of 
severity 
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Figure 5: Discriminating between quiescent vs. mild histological disease 
 
ROC curves indicating the diagnostic accuracy of each individual endoscopic scoring 
system in predicting quiescent histological disease activity vs. mild/moderate/severe 
disease collectively (total n = 450 individual rater responses; 15 participants and 30 
videos in the post-training module) [A]; and discriminated against mild histological 
disease only (total n = 255 individual rater responses; 15 participants and 17 videos in the 
post-training module). 
 
The post-training module consisted of videos capturing quiescent (n = 10), mild (n = 7), 
moderate (n = 6) and severe (n = 7) histological disease. Single asterisk denotes 
statistical significance in ROC curve analysis with a p value of <0.001. AUROC, area 
under the ROC curve; CI, confidence interval; PICaSSO, Paddington International virtual 
ChromoendoScopy ScOre; ROC, receiver operator characteristic; UCEIS, ulcerative 
colitis index of disease severity. 
 
Figure 6.  Representative photos of  different grade of inflammation captured using 
HD and NBI  
 
 
Figure 7. Representative photo of  different grade of inflammation captured using 
HD and  BLI ( Courtesy of A.Repici and F.Furfaro Humanitas  University, Milan, Italy) 
 
Figure 8. Representative photos of different grade of inflammation captured using 
HD and iSCAN OE   
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Supplementary Table 1: Percentage rater agreement across histological strata (post-
training; round 1) 
 
Histological strata
*
 Overall  
agreement  0 1 2 3 
Mayo score 56.1% 52.8% 51.9% 77.0% 59.4% 
UCEIS total score 44.0% 31.2% 25.9% 35.5% 35.4% 
- UCEIS vascular pattern 47.2% 48.8% 46.7% 58.1% 50.0% 
- UCEIS bleeding pattern  93.9% 57.8% 36.3% 54.1% 64.7% 
- UCEIS erosion/ulcer pattern  86.4% 76.7% 52.5% 52.8% 69.5% 
PICaSSO mucosal (full) 39.6% 27.3% 22.5% 51.6% 36.1% 
PICaSSO-Ab. mucosal (abbreviated 
version) 86.3% 79.2% 60.3% 83.1% 78.7% 
PICaSSO vascular (full) 24.7% 22.6% 24.0% 49.1% 29.7% 
PICaSSO-Ab. vascular (abbreviated 
version) 58.1% 42.7% 42.5% 67.3% 53.5% 
 
 
Percentage (%) agreement across each histological strata determine by evaluating every 
possible rate combination (n = 15 raters; 105 possible rater combinations). 
*
Histological strata according to the New York Mt. Sinai scoring system.
23
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Supplementary Table 2A: Percentage rater agreement across histological strata 
(post-training; round 1) 
 
Histological strata
*
 Overall  
agreement  0 1 2 3 
Mayo score 51.9% 47.6% 56.5% 86.5% 59.9% 
UCEIS total score 38.6% 28.6% 25.9% 45.2% 35.3% 
- UCEIS vascular pattern 42.8% 49.2% 48.6% 69.8% 51.8% 
- UCEIS bleeding pattern  90.6% 54.8% 38.9% 60.7% 64.9% 
- UCEIS erosion/ulcer pattern  85.6% 77.8% 52.3% 57.5% 70.6% 
PICaSSO vascular; full 24.4% 24.6% 22.7% 52.0% 30.6% 
PICaSSO vascular; abbreviated 54.2% 36.5% 43.1% 70.6% 51.7% 
PICaSSO mucosal; full 43.3% 28.6% 24.5% 57.8% 39.4% 
PICaSSO mucosal; abbreviated 82.2% 81.7% 62.0% 88.5% 79.5% 
Percentage (%) agreement across each histological strata determine by evaluating every 
possible rate combination (n = 9/15 raters who participated in both round 1 and round 2; 
36 possible rater combinations). 
*
Histological strata according to the New York Mt. Sinai scoring system.
23
 
 
 
 
Supplementary Table 2B: Percentage rater agreement across histological strata 
(round 2) 
 
Histological strata
*
 Overall 
agreement  0 1 2 3 
Mayo score 70.0% 55.2% 53.2% 83.8% 69.0% 
UCEIS total score 53.0% 33.0% 37.0% 34.6% 41.2% 
- UCEIS vascular pattern 59.6% 59.4% 59.3% 73.9% 64.0% 
- UCEIS bleeding pattern  94.4% 53.5% 64.4% 47.9% 67.9% 
- UCEIS erosion/ulcer pattern  89.8% 61.1% 55.6% 63.0% 71.2% 
PICaSSO vascular; full 29.6% 31.9% 20.4% 39.7% 31.9% 
PICaSSO-Ab. vascular (abbreviated version) 67.0% 40.6% 45.8% 60.5% 56.9% 
PICaSSO mucosal; full 42.0% 21.2% 17.1% 54.9% 38.5% 
PICaSSO-Ab. mucosal (abbreviated version) 89.8% 63.2% 68.1% 82.1% 79.2% 
Percentage (%) agreement across each histological strata determine by evaluating every 
possible rate combination (n = 9/15 raters who participated in both round 1 and round 2; 
36 possible rater combinations). 
 
*
Histological strata according to the New York Mt. Sinai scoring system.
23
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Supplementary Table 3: Accuracy of PICaSSO in discriminating quiescent vs. 
mild histological disease  
 
Criterion Cut-point  Sensitivity  Specificity  
Mayo endoscopic sub score  0 68% 68% 
UCEIS total score 3 99% 10% 
- UCEIS vascular pattern 1 39% 68% 
- UCEIS bleeding pattern  1 97% 32% 
- UCEIS erosion/ulcer pattern  1 93% 47% 
PICaSSO vascular 0C 83% 47% 
PICaSSO mucosal 0C 97% 45% 
PICaSSO, Paddington International virtual ChromoendoScopy ScOre; UCEIS, ulcerative 
colitis endoscopic index of disease severity. 
 
